Charles Edward Hart
Direttore operativo presso HighCape Capital LP
Profilo
Charles Edward Hart is currently an Operating Partner at HighCape Capital LP.
He previously worked as a Senior Director-Investor Relations at ZymoGenetics, Inc., Director at Biorez, Inc., Vice President-Research at Shire Pharmaceuticals, Inc., and Chief Scientific Officer & Vice President at BioMimetic Therapeutics, Inc. and Shire Regenerative Medicine, Inc. He holds a doctorate degree from the University of Washington, a graduate degree from Oregon State University, and an undergraduate degree from the University of California, Davis.
Posizioni attive di Charles Edward Hart
Società | Posizione | Inizio |
---|---|---|
HighCape Capital LP
HighCape Capital LP Financial ConglomeratesFinance HighCape Capital LP is a growth equity fund based in New York, NY. HighCape Capital is dedicated to helping innovative life sciences companies transition into successful and thriving organizations. HighCape Capital LP was founded in 2013 by Kevin L. Rakin and he has been the CEO since 2013. | Direttore operativo | - |
Precedenti posizioni note di Charles Edward Hart
Società | Posizione | Fine |
---|---|---|
Shire Regenerative Medicine, Inc.
Shire Regenerative Medicine, Inc. BiotechnologyHealth Technology Shire Regenerative Medicine, Inc. develops and commercializes living cell therapies. It manufactures and markets dermagraft, a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body's natural healing process. The company was founded in 2004 and is headquartered in Westport, CT. | Direttore Tecnico/Scientifico/R&S | 01/01/2011 |
BioMimetic Therapeutics, Inc.
BioMimetic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioMimetic Therapeutics, Inc. developed and sells protein therapeutics for tissue and organ regeneration. The company was founded by Samuel E. Lynch and David M. Renzi on April 14, 1999 and was headquartered in Franklin, TN. | Direttore Tecnico/Scientifico/R&S | 01/01/2008 |
Biorez, Inc.
Biorez, Inc. Medical SpecialtiesHealth Technology BioRez, Inc. engages in the design and development of resorbable polymer scaffold technology. The firm offers a device that is suited for tendon, ligament, and other soft tissue injuries. The company was founded by Cato T. Laurencin and Joseph W. Reilly in 2008 and is headquartered in New Haven, CT. | Direttore/Membro del Consiglio | - |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Direttore Tecnico/Scientifico/R&S | - |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Contatto Relazioni con gli Investitori | - |
Formazione di Charles Edward Hart
University of Washington | Doctorate Degree |
Oregon State University | Graduate Degree |
University of California, Davis | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 6 |
---|---|
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
Biorez, Inc.
Biorez, Inc. Medical SpecialtiesHealth Technology BioRez, Inc. engages in the design and development of resorbable polymer scaffold technology. The firm offers a device that is suited for tendon, ligament, and other soft tissue injuries. The company was founded by Cato T. Laurencin and Joseph W. Reilly in 2008 and is headquartered in New Haven, CT. | Health Technology |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Shire Regenerative Medicine, Inc.
Shire Regenerative Medicine, Inc. BiotechnologyHealth Technology Shire Regenerative Medicine, Inc. develops and commercializes living cell therapies. It manufactures and markets dermagraft, a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body's natural healing process. The company was founded in 2004 and is headquartered in Westport, CT. | Health Technology |
BioMimetic Therapeutics, Inc.
BioMimetic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioMimetic Therapeutics, Inc. developed and sells protein therapeutics for tissue and organ regeneration. The company was founded by Samuel E. Lynch and David M. Renzi on April 14, 1999 and was headquartered in Franklin, TN. | Health Technology |
HighCape Capital LP
HighCape Capital LP Financial ConglomeratesFinance HighCape Capital LP is a growth equity fund based in New York, NY. HighCape Capital is dedicated to helping innovative life sciences companies transition into successful and thriving organizations. HighCape Capital LP was founded in 2013 by Kevin L. Rakin and he has been the CEO since 2013. | Finance |
- Borsa valori
- Insiders
- Charles Edward Hart